Last reviewed · How we verify

UMEC/VI DPI — Competitive Intelligence Brief

UMEC/VI DPI (UMEC/VI DPI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA). Area: Respiratory / Pulmonology.

marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

UMEC/VI DPI (UMEC/VI DPI) — GlaxoSmithKline. UMEC/VI is a combination of umeclidinium (a long-acting muscarinic antagonist) and vilanterol (a long-acting beta-2 agonist) that relaxes airway smooth muscle and improves airflow in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
UMEC/VI DPI TARGET UMEC/VI DPI GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)
UMEC/VI UMEC/VI GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor
Umeclidinium/Vilanterol 62.5/25 mcgs Umeclidinium/Vilanterol 62.5/25 mcgs National Institute of Respiratory Diseases, Mexico marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
Umeclidinium / Vilanterol Dry Powder Inhaler Umeclidinium / Vilanterol Dry Powder Inhaler Gary L. Pierce marketed Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
TIO/OLO TIO/OLO GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor and beta-2 adrenergic receptor
Revefenacin 175 µg, Formoterol 20 µg Revefenacin 175 µg, Formoterol 20 µg University of Tennessee Graduate School of Medicine marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
Tiotropium & olodaterol Tiotropium & olodaterol University of Dundee marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) class)

  1. GlaxoSmithKline · 5 drugs in this class
  2. University of Dundee · 2 drugs in this class
  3. National Institute of Respiratory Diseases, Mexico · 1 drug in this class
  4. University of Tennessee Graduate School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). UMEC/VI DPI — Competitive Intelligence Brief. https://druglandscape.com/ci/umec-vi-dpi. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: